Used in the treatment of wet age-related macular degeneration (wet AMD) and other ocular diseases involving abnormal blood vessel growth. It works by inhibiting angiopoietin-2 (ANGPT2), a protein that contributes to vascular instability and inflammation in the retina. By blocking ANGPT2, the antibody helps reduce vascular leakage, supports vascular normalization, and may improve outcomes when combined with anti-VEGF therapies. Investigated in clinical trials for its potential to enhance visual acuity and reduce treatment burden in patients requiring frequent anti-VEGF injections. Also explored in oncology for its role in disrupting tumor angiogenesis and improving the tumor microenvironment for better therapeutic response.